The jump from 0.25 mg to 0.5 mg represents a doubling of your dose
GLP-1 medications like semaglutide are synthetic versions of this hormone, designed to amplify its effects and help the body function in a more regulated, balanced way
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial
25 , 36 Such studies suggest that semaglutide directly activates brain areas that are accessible to the molecule and also causes indirect secondary modulation of neuronal activity in other brain areas, including those involved in appetite regulation, food intake, food preference, reward and meal termination, such as the lateral parabrachial nucleus
Tolerance development - Some individuals find that appetite suppression diminishes over time, requiring dose adjustments or additional strategies Maintenance is a separate challenge - Many people regain weight after discontinuing GLP-1 medications
